Zdrowie i gospodarka · 15.04.2022
Bioavailability Studies Submitted in NDAs or INDs-General Considerations; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Bioavailability Studies Submitted in NDAs or INDs--General Considerations." This guidance provides recommendations to sponsors planning to include bioavailability (BA) information for drug products in investigational new drug applications (INDs), new drug applications (NDAs), and NDA supplements. This guidance finalizes the draft guidance of the same title issued on February 26, 2019. This guidance also replaces the draft guidance entitled "Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs--General Considerations" issued March 2014.